C4X Discovery's Nick Ray promoted to CSO

10 January 2023
nick_ray_large

A UK drug discovery company has announced the appointment of a chief scientific officer (CSO).

C4X Discovery (AIM: C4XD) has promoted Nick Ray (pictured) to the role. He has been credited with playing a key part in the company’s growth since joining the firm in 2016.

A medicinal chemist by training, Dr Ray is currently the company’s senior vice president (SVP) for drug discovery, leading the medicinal chemistry, structural analysis and computational chemistry teams.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical